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Abstract
Introduction: Chondrosarcomas and chordomas are usually chemoresistant bone tumors and
may have a poor prognosis when advanced. They are usually associated with worsening pain difficult
to control.
Patients and Methods: Zoledronic acid was used in a 63-year-old man with metastatic
chondrosarcoma and in a 66-year-old woman with a diagnosis of sacrum chordoma both reporting
severe pain related to tumor.
Results: In the first case, zoledronic acid was able to maintain pain control despite disease
progression following chemotherapy, in the other case, zoledronic acid only produced significant
clinical benefit.
Conclusion: Control of pain associated with bone tumors such as chondrosarcoma and
chondroma may significantly improve from use of zoledronic acid, independently from tumor
response to other treatments. Evaluation on larger series are needed to confirm the clinical effect
of this bisphosphonate on such tumors.
Background
Malignant tumors arising from the skeletal system are
rare, representing only 0.2% of all new cancers [1]. Bone
tumors are classified by cell type and recognized products
of proliferating cells. Chondrogenic tumors account for
about 21% of bone tumors. Chondrosarcoma is a malig-
nant cartilage forming tumor. Conventional chondrosar-
coma is the most frequent type of chondrosarcoma and
may develop centrally within the medullary cavity (pri-
mary or central chondrosarcoma) or within the cartilage
cap of a pre-existing osteochondroma (secondary or
peripheral chondrosarcoma). Most chondrosarcomas
develop in the thoracic, pelvic and long bones. Grade is
the single most important predictive factor for local recur-
rence and metastasis. Chordoma arises from remnants of
notochord and is very rare representing about 3% of bone
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throughout the midline with 50% occurring in the sacro-
coccygeal region, approximately 35% in the skull base
and about 15% in the mobile vertebral column [2]. Both
tumors may have a severe prognosis when advanced
because of limited curative therapies, poor functional out-
come and severe pain. When feasible, aggressive surgery
represents the best chance of cure. However, recurrence
rate are high. Resistance to chemotherapy makes even
more difficult management of sarcoma.
Bisphosphonates are known to inhibit osteoclast-medi-
ated bone resorption and osteoblast differentiation. The
evolution of bisphosphonates has led to the development
of nitrogen-containing bisphosphonates (N-BPs) which
have a different mechanism of action in comparison from
that of older nonnitrogen-containing bisphosphonates
[3]. N-BPs include pamidronate, alendronate, ibandro-
nate, risedronate and zoledronic acid. Zoledronic acid is
the most potent bisphosphonate known to date and has
shown to be between 87-fold and 940-fold more potent
than pamidronate in animal models of bone resorption
[4].
N-BPs exert their effects on osteoclasts and tumor cells by
inhibiting a key enzyme in the mevalonate pathway, far-
nesyl disphosphate synthase, thus preventing protein pre-
nylation and activation of intracellular signalling proteins
such as ras [3]. In particular, inhibition of protein prenyla-
tion and ras signalling within osteoclasts leads to defects
in intracellular vesicle transport. As an example, osteo-
clasts became defective as concerns ruffled borders which
is required for bone resorption.
Bisphosphonates induce caspase-dependent apoptosis,
inhibit metalloproteinase activity and have antiang-
iogenic properties. Reduction in Vascular Endothelial
Growth factor (VEGF) levels was showed during pamidr-
onate treatment in cancer patients [5].
The intense effect exerted within bone microenvironment
may have a great result not only for metastatic but also for
primitive tumors of bone. Recent reports support a direct
antitumor activity by zoledronic acid. This effect was doc-
umented in cellular and animal models of osteosarcoma
[6-8]. Zoledronic acid, paclitaxel alone or associated were
tested in a murine model of Ewing sarcoma [8]. Tumor
growth was showed in 78% of rats treated with paclitaxel,
44% of rats treated with zoledronic acid and 22% of rats
treated with zoledronic acid plus paclitaxel [8]. In this
study, paclitaxel and zoledronic acid act synergically
despite the minimal antitumor activity of paclitaxel in sar-
comas. Therefore the activity of some chemotherapeutic
agents may improve in association with zoledronic acid.
Many reports are in line with this suggestion [6,8,10]. Pre-
clinical models of chondrosarcoma confirm the effect of
zoledronic acid [11]. Insights into molecular mechanisms
have demonstrated DNA-damage S-phase checkpoint and
up-regulation of mitochondrial permeability independ-
ently of p53 and retinoblastoma status [12]. Therefore,
zoledronic acid can inhibit cell proliferation and induce
apoptosis in tumors where these mutations frequently
occur.
Skeletal-related events and bone pain share the same
underlying origin. The inhibition of tumor-induced bone
resorption by N-BPs produce significant reduction in skel-
etal morbidity and bone pain [13]. Usually pain is the first
symptom of metastatic involvement of bone by tumor.
Pain could increase gradually and treatment with opioids
or palliative radiation therapy may be required. Typically,
bone pain is not adequately managed and 75%–95% of
patients with advanced cancer experience severe pain [13].
Treatment with zoledronic acid provides substantial ben-
efit in terms of pain relief in patients with bone metastases
by various tumors [14,15].
Zoledronic acid was currently approved worldwide for the
treatment of bone metastases independent of the primary
tumor type. However, there is no reported clinical experi-
ence concerning chondrosarcoma and/or chordoma until
now.
Following we report on a 63-year-old man patient with
advanced chondrosarcoma and a 66-year-old woman
with sacrum chordoma treated with zoledronic acid.
Case presentation
In 2006, a 63-year-old Caucasian man referred a painful
swelling at level of right thorax developed during the last
month. He was under cardiologic control for mild heart
failure. By Computer Tomography (CT) examination a
lesion measuring 15 cm maximum diameter involving
muscles and ribs was showed. The lesion appeared calci-
fied (fig. 1a and 1b). Concomitant lung metastases, some
of them with calcifications, and right pleural effusion
were showed (fig. 1a). Bone scintigraphy displayed ligand
uptake in the right thorax. Fine needle biopsy revealed
spindle cell neoplasm being immunohistochemically
positive for vimentin and negative for citokeratin pan and
S-100. This tumor was defined as a low grade chondrosa-
rcoma. The patient refused further diagnostic procedures.
He reported relentless pain corresponding to the tumor
location with increasing need for analgesic drugs. The
patient started a chemotherapy regimen based on ifosfa-
mide and uromitexan with monthly zoledronic acid
(Zometa; Novartis Pharma, Origgio, Italy) administra-
tion. After the first cycle the patient reported a significant
benefit on pain and the need for analgesic drugs progres-
sively tapered until stopping. This benefit was confirmedPage 2 of 4
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a Thoracic CT scan in the patient with chondrosarcoma shows at right the lesion involving muscles and ribsFigure 1
a Thoracic CT scan in the patient with chondrosarcoma shows at right the lesion involving muscles and ribs. 
Lung metastases were visualized. b Coronal section displays the large tumor.
Pelvic CT scan in the patient with chordoma shows the lesion infiltrating the sacrumFigure 2
Pelvic CT scan in the patient with chordoma shows the lesion infiltrating the sacrum.
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ble disease after three months and progression after six
cycles. Therefore zoledronic acid was maintained while
chemotherapy was stopped. However, pain always
remained under control until zoledronic acid was admin-
istered, that is for further three months after chemother-
apy stopping when the patient died.
In 2002, a 66-year-old Caucasian woman with a history of
epilepsy presented progressive lower back pain with irra-
diation to lower extremities. By sacrum biopsy vacuoled
cells having a medium and large size were showed in an
abundant myxoid background. These tumor cells were
immunohistochemically positive for citokeratin, vimen-
tin and Epithelial Membrane Antigen (EMA) and were
weakly positive for S-100. These findings were considered
indicative for a sacrum chordoma. The tumor was consid-
ered unresectable and treated with radiotherapy. In 2005,
despite disease stability by CT scans, the patient com-
plained persisting pain to the sacrum refractory to analge-
sic, opioids and antiepileptic drugs. Zoledronic acid was
started. After few days the patient reported a significant
pain reduction. This effect appeared to decrease 20 days
after the administration. Therefore, a 21 day-interval of
zoledronic acid administration was chosen. The tumor
appeared unchanged until now (fig. 2)
Conclusion
The cases previously reported showed that zoledronic acid
may impact on pain related to tumor and quality of life of
these patients independently from other administered
therapies and disease control. In the patient with chond-
rosarcoma, chemotherapy and zoledronic acid were con-
comitantly administrated, therefore the effect of each one
cannot be evaluated. However, when the patient pro-
gressed, zoledronic acid only was able to maintain pain
control.
Zoledronic acid may help in relieving pain related to bone
tumors such as chondrosarcoma and chordoma. Studies
including more patients are needed to detect the clinical
effect of zoledronic acid. However, zoledronic acid
appeared to be safe and effective in improvement of pain
in the cases described.
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